Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products in ASEAN countries. This segment focuses on various therapeutic areas, such as dermatology, pediatrics and neonatology, allergy, otorhinolaryngology, orthopedics and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, psychiatry, family medicine, and medical aesthetics. Its Proprietary Brands segment develops, markets, and sells dermatological products comprising Ceradan, TDF, and CG210; health supplements under the Ocean Health brand covering areas, such as heart, joint, physical, cognitive, eye, and health; and pharmaceuticals. The Digital Platform and E-Pharmacy segment operates a digital platform that services procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies primarily in Singapore. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore.